Impact of Reclassification of Oncocytic and Follicular Thyroid Carcinoma by the 2022 WHO Classification.
Merel T StegengaLindsey OudijkEvert F S van VelsenRobin P PeetersMarco MediciFrederik A VerburgTessa M van GinhovenFolkert van KemenadeW. Edward VisserPublished in: The Journal of clinical endocrinology and metabolism (2024)
Classification of OTC and FTC into three subcategories as defined by the 2022 WHO Classification substantially improves discrimination between low, intermediate and high risk patients, especially for DSS and RAI-refractory disease.